Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, will be presenting at the upcoming 2023 BIO International Convention in Boston.
Purolite, an Ecolab company based in Pennsylvania, is a leading manufacturer of healthcare, pharmaceutical and life science products. Its affinity and ion exchange resins are used in various purification processes in the manufacture of biologics.
Sania Therapeutics, a new biotech company focused on developing genetic medicines for neural circuit dysfunction, has launched by unveiling its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.
Amgen joins the Winn Award Program that was set up by Bristol Myers Squibb, with plans to extend the reach of clinical trials into underserved patient populations in the US.
The research institutions are joining on a community-based collaborative initiative to work toward greater study inclusion, supported by funding from PhRMA.
Recruiting and nurturing talent will be incredibly important in the biosimilar industry as it continues its rapid evolution, according to RSA Talent Equity.
The pharmaceutical company is expanding its alliance with historically Black medical schools to bolster the battle against systemic health disparities.
The Biotechnology Innovation Organization elected the fresh slate of leaders during the BIO International Convention, taking place in San Diego this week.
Unveiled at the 2022 BIO International Convention, the group's third annual diversity, equity, and inclusion report spotlights improvements both made and needed.
A leader from the organizer of the pharmaceutical event discusses what’s in store for the upcoming conference, and for the drug development industry itself.
CPhI North America 2022 host city Philadelphia is set to become one of the world’s biggest cell and gene therapy manufacturing hubs. But it’s just one of many centers of innovation that are helping drive the US pharma and biopharma industry.
‘Open science’ encourages the public sharing of research data, helping researchers tackle biological threats. And yet, as the biotech industry moves forward in leaps and bounds, the risk of accidental or deliberate misuse of biological research increases....
Syner-G BioPharma Group, a provider of Chemistry, Manufacturing, and Controls (CMC) technical, regulatory, and compliance consulting services to the pharmaceutical and biotechnology industry, has acquired Impact Pharmaceutical Services.
The global pharmaceutical industry event is returning to the real world November 9-11 this year, with online content for professionals opting not to travel.
Open Pharma wants to see articles in peer-reviewed medical journals provide plain language summaries: those written in everyday language that is easy to understand by anyone from patients to policymakers. It's now set out its recommendations on how...
Whether working in the pharmaceutical industry or in academia or government, the skills required to achieve, maintain and grow a career are vastly different today than they were 30 years ago. A session at DIA 2021 will put the spotlight on the skills...
Thanks in part to swift COVID-19 response and relatively low infection rates, more sites and sponsors are looking at the region to locate their studies.
California information technology and services company Syntegra and the National Institutes of Health (NIH) have signed a partnership to 'democratize access to the largest set of COVID-19 patient records': with the use of Syntegra's synthetic...
Venom from honeybees has been found to rapidly destroy triple-negative breast cancer and HER2-enriched breast cancer cells – with minimal effect on healthy cells, according to a study published this month.
Researchers discover scorpion toxin that triggers pain through a previously unknown pathway, potentially opening up new avenues of investigation for treating chronic pain.
As the cell and gene therapies market evolves, CDMOs and pharmaceutical companies aim to adapt to the rising demands and serve larger patient populations.
Diverse leadership provides more opportunity for innovation and higher performance in financial return, says diversity and inclusion chair and biotech executive.
